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Cancer associated retinopathy (CAR) belongs to
paraneoplastic syndromes resulting in progressive loss of
vision and clinical signs of retinal degeneration. The
syndrome was first described by Sawyer and associates
in 1976, and since that time many cases have been
reported in association with various systemic malignances
such as: small cell lung cancer, non-small cell lung cancer,
breast cancer, invasive thymoma, uterine cervical cancer,
endometrial cancer, lymphoma [1-11].
The conjectural pathogenesis of cancer- associated
retinopathy has been confirmed by in vitro and in vivo
experiments using rat models [12,13]. CAR is considered
to be an autoimmune disorder that involves cross-
reaction between autoantibodies and retinal proteins such
as recoverin. Recoverin is a 23 kD calcium binding
protein found in rods and cones which plays a critical
role in the visual sensory response. It plays a major role in
light and dark adaptation by regulating rhodopsin
phosphorylation and dephosphorylation in a calcium
dependent manner. Recoverin gene was mapped to the
human chromosome 17 by Murakami and associates in
1992 and localized by Mc Ginns and associates at position
17p13.1, which is a region containing a number of cancers
related loci [14,15]. Production of antirecoverin antibodies
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Cancer associated retinopathy (CAR) is one of the paraneoplastic syndromes. An important factor of its pathogenesis is the
cross-reaction between the autoantibodies and retinal proteins such as recoverin. Recoverin, a calcium binding protein
found in cones and rods, is responsible for the adaptation to light and darkness. Expression of recoverin in cancerous tissues
stimulates the production of antirecoverin antibodies, which penetrate into retinal photoreceptor cells and cause misregulation
of the phototransduction pathway and induction of apoptotic death. The triad of characteristic CAR symptoms includes
photosensitivity, ring scotomatous visual field loss and attenuated arteriolae caliber. CAR may usually be observed before the
diagnosis of cancer, but it is possible to recognize it after primary malignancy detection. Ophthalmologic examination,
Goldmann perimetry, ERG, MERG, and antirecoverin titers are recommended in the course of diagnosis. CAR therapy
includes not only primary carcinoma treatment, but also methods typically applied in autoimmune disorders, such as:
systemic corticosteroid therapy, plasmapharesis and intravenous immunoglobulin.
Retinopatia paranowotworowa
Retinopatia paranowotworowa (CAR) zaliczana jest do zespo∏ów paraneoplazmatycznych. G∏ównà rol´ w jej patogenezie
odgrywa reakcja krzy˝owa pomi´dzy antygenami siatkówki, (jak rekoweryna), a przeciwcia∏ami przeciw nim skierowanymi.
Rekoweryna, proteina wià˝àca wapƒ, jest komponentà czopków i pr´cików. Odgrywa kluczowà rol´ w adaptacji do Êwiat∏a i
ciemnoÊci. Ekspresja rekoweryny  przez tkanki nowotworowe stymuluje produkcj´  przeciwcia∏ anty-rekowerynowych.
Przeciwcia∏a te penetrujà przez barier´ krew-siatkówka i docierajà do warstwy komórek Êwiat∏oczu∏ych, powodujàc zaburzenia
procesu fototransdukcji i indukcj´ apoptozy. Nadwra˝liwoÊç na Êwiat∏o, mroczki pierÊcieniowe w polu widzenia, zw´˝enie
naczyƒ t´tniczych dna oka stanowi charakterystycznà triad´ objawów CAR. Retinopatia paranowotworowa zwykle jest
obserwowana przed wykryciem nowotworu, lecz znane sà równie˝ doniesienia rozwini´cia objawów CAR jako nast´pstwa
pierwotnego  procesu z∏oÊliwego. Bardzo pomocnymi i zalecanymi narz´dziami diagnostycznym sà: badanie okulistyczne,
perymetria Goldmana, ERG (elektroretinografia), MERG (wieloogniskowa elektroretinografia), oznaczanie poziomu
przeciwcia∏ anty-rekowerynowych. Leczenie CAR zak∏ada nie tylko leczenie pierwotnego procesu nowotworowego, lecz
równie˝ w∏àczenie terapii stosowanych w leczeniu chorób autoimmunologicznych, czyli sterydoterapii ogólnej, plazmafarezy
i wlewów do˝ylnych immunoglobulin. 
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is stimulated by expression of recoverin in cancerous
tissues. There is a hypothesis that single mutational event
inactivates a copy of the p53 suppressor gene, which turns
on the synthesis of recoverin protein. 23 kD epitopes
synthesized outside the eye evoke production of
circulating antibodies [15]. The antirecoverin antibodies
penetrate into the retina’s photoreceptor cells through
the peripheral circulation and block recoverin function,
causing misregulation of the phototransduction pathway,
and induction of apoptotic death. It is proved that
antirecoverin antibodies are the inducers of retinal cell
apoptosis via the caspase 9- and caspase 3- dependent
way [16]. However, it has to be noticed that not only
antirecoverin antibodies can be detected in serum of
patients with CAR but also antibodies against enolase, 34
kD, 46 kD, 60 kD, 65 kD or 70 kD protein [7,10,17-19].
The main manifestation of CAR is rapid, progressive
bilateral visual loss, although some patients initially
present with only one affected eye. Complaints refer to
both rod and cone dysfunction. Clinical problems
associated with cone dysfunction include photosensitivity,
abnormal visual acuity, color vision abnormalities as well
as central scotomas, and an abnormal cone- mediate
electroretinogram (ERG). Clinical problems associated
with rod dysfunction include nyctalopia, prolonged dark
adaptation, peripheral or ring scotomas and an abnormal
rod-mediated ERG [4, 20].
The results of ophthalmologic examination often
show a triad of symptoms: photosensitivity, ring scoto-
matous visual field loss and attenuated retinal arteriole
calibre [22]. Fundus finding in-patients are not specific,
and could reveal normal fundus examination, optic disc
pallor, narrowing of the retinal arterioles and the retinal
pigment epithelium changes [4,18, 20, 22].
Fluorescein angiography may demonstrate pro-
gressive diminution of peripheral retinal blood flow, slow
perfusion and staining of venules [3]. Electrooculography
presents reduced light peak/dark trough ratio [23].
Electroretinography (ERG), which is helpful in most
cases, shows reduction of amplitudes in cone and rod-
mediated response. Multifocal electroretinography
(MERG) may be useful in cases where the visual field
loss is localized. In some cases MERG was used to
quantitative the loss of electrical activity and to correlate
this to Goldmann perimetry. Laboratory investigation to
detect antirecoverin antibodies in serum is recommended
to establish diagnosis [6].
Patients with CAR require treatment for primary
carcinoma. However, it is not uncommon for CAR
patients to develop visual loss before detecting
malignancy. Rising antibody titers may be considered as
indication for therapy. A gold standard for treatment
does not exist. Typical treatment used in autoimmune
disorders such as: systemic corticosteroid therapy,
plasmapheresis, and intravenous immunoglobulin (IVIG)
is recommended [18, 24-26]. More than half of the
patients respond with visual improvement and antibody
titers reduced to normal after Prednisone. Combined
therapy with oral corticosteroids and plasmapheresis may
result in a recovery of vision, as well as IVIG, which
appear to provide beneficial effects. Patients with CAR
treated both with Prednisone and plasmapheresis without
response had a dramatic response to IVIG [26]. The
effective methods of treatments are still a subject of many
researches.
CAR is being increasingly recognized over the last 27
years, since Sawyer’s discovery. Similar to other
paraneoplastic disorders, cancer- associated retinopathy is
most often associated with underlying small-cell
carcinoma of the lung although it has been report to
accompany a number of other malignancies.
CAR is usually observed before the diagnosis of
cancer, as was reported in most cases of small-sell lung
carcinoma, invasive thymoma, and uterine cervical cancer
[1-3, 7, 11]. In a few cases it has been recognized after the
detection of the primary malignancy. A good example of
cancer-associated retinopathy developing after carcinoma
detection is offered by the case of a 65- year-old man
who underwent resection of adenocarcinoma of the lung.
Ten months later he complained of deterioration of vision
[4]. A similar situation was reported in two patients with
breast cancer – both presenting with paraneoplastic
retinopathy. However, in these cases immunology tests
showed antiretinal antibodies, which failed to react with
the 23 kD retinal antigen recoverin [5]. Sometimes CAR
detection in breast cancer can be more complicated.
Sadowski et al. report the case of an 84-year-old patient
with breast and colon cancer, who complained of
a decrease in visual acuity after treatment with low-dose
antiestrogens. Side effects of tamoxifene were suspected,
but after fundus and visual field examination and ERG &
MERG the paraneoplastic syndrome was diagnosed [6].
CAR should focus not only the attention of the
ophthalmologists, but also that of the oncologist. If
a patient with cancer complains of “dimming” of vision
with missing areas of the visual field, central and
cecocentral scotomas, hemeralopia, photopsias, night
blindness, loss of color vision and/or photosensitivity CAR
must always be considered. Laboratory examination for
CAR is necessary in all such cases. By way of analogy in-
patients presenting ocular CAR-like symptoms ought to
be diagnosed for cancer.
Detecting and monitoring antiretina titers can be
useful in patient management, especially in order to
estimate retinal function. Reducing the antibody response
carries a potential risk of increasing cancer mortality,
however those are only suspicions, and not clinically
documented examples. 
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